Trials / Completed
CompletedNCT03727139
Rasagiline Tablets Special Drug Use-Results Survey "Survey on Long-term Safety"
AZILECT Tablets Special Drug Use-Results Survey "Survey on Long-term Safety"
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,021 (actual)
- Sponsor
- Takeda · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this survey is to evaluate the long-term safety of Rasagiline (AZILECT) in patients with Parkinson's disease in daily clinical practice and also collect efficacy information.
Detailed description
The drug being tested in this survey is called rasagiline tablet. This tablet is being tested to treat people with Parkinson's disease. This survey is an observational (non-interventional) study and will look at the long-term safety and efficacy of the rasagiline tablet in the routine clinical setting. The planned number of observed patients will be approximately 1000. This multi-center observational trial will be conducted in Japan.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rasagiline | Rasagiline Tablets |
Timeline
- Start date
- 2018-11-01
- Primary completion
- 2021-10-31
- Completion
- 2021-10-31
- First posted
- 2018-11-01
- Last updated
- 2024-03-08
- Results posted
- 2024-03-08
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT03727139. Inclusion in this directory is not an endorsement.